AcelRx had planned to raise $86m in its initial public offering (IPO) but is now offering eight million shares at $5 each, with a further 1.2 million available if there is enough demand, according to its regulatory filing.

The company sold 7.15 million common shares at its initial public offering (IPO) at $15 each, according to Gevo's regulatory filing.

Out of 240 portfolio companies at Intel Capital, 12 are listed in the US with the three largest holdings as Micron Technology, VMWare and Clearwire, according to the company's regulatory filing.

Investment bank UBS is advising on the flotation of Jucheng, the first training services company to list in China.

BG Medicine plans to list 4.75 million shares for $7 each at its initial public offering (IPO), although investment bank Lazard can sell a further 712,500 shares if demand is strong enough. The previous price range was $13 to $15 per share.

Fluidigm will offer 5.17 million common shares when it floats on the Nasdaq stock exchange at between $13.50 and $15.50 per share.

New York or Nasdaq could be flotation route for social network LinkedIn after it files for initial public offering

AcelRx will issue 6.6 million shares at up to $14 each to raise $92.9m, including 865,500 shares the investment bank Piper Jaffray can sell if demand is strong enough. After the initial public offering (IPO), AcelRx will have a market capitalisation of up to $230m based on 16.1 million shares in issuance.

The company will sell 7.15 million common shares at its initial public offering (IPO) at between $13 and $15 each, according to Gevo's regulatory filing.

Newswire Reuters said a prospectus for LinkedIn's initial public offering was expected to be completed by end-March with the three banks as book-runners selling its shares to the public.